{"nctId":"NCT00522379","briefTitle":"Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch","startDateStruct":{"date":"2007-07"},"conditions":["Parkinson's Disease"],"count":514,"armGroups":[{"label":"Rotigotine 2 mg/24 hr","type":"EXPERIMENTAL","interventionNames":["Drug: Rotigotine"]},{"label":"Rotigotine 4 mg/24 hr","type":"EXPERIMENTAL","interventionNames":["Drug: Rotigotine"]},{"label":"Rotigotine 6 mg/24 hr","type":"EXPERIMENTAL","interventionNames":["Drug: Rotigotine"]},{"label":"Rotigotine 8 mg/24 hr","type":"EXPERIMENTAL","interventionNames":["Drug: Rotigotine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Rotigotine","otherNames":["Neupro"]},{"name":"Rotigotine","otherNames":["Neupro"]},{"name":"Placebo","otherNames":[]},{"name":"Rotigotine","otherNames":["Neupro"]},{"name":"Rotigotine","otherNames":["Neupro"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* PD greater than 3 years\n* Stable dose L-dopa but symptoms not adequately controlled and have \"off\" time\n* Able and willing to complete diary on specific days\n\nExclusion Criteria:\n\n* Previous use of rotigotine or Neupro\n* Atypical Parkinson's syndrome\n* Pallidotomy\n* Thalamotomy\n* Deep brain stimulation\n* Fetal tissue transplant\n* Dementia\n* Psychosis\n* Hallucinations\n* Epilepsy\n* Renal or hepatic dysfunction\n* Clinically relevant cardiac dysfunction\n* Symptomatic orthostatic hypotension\n* Skin sensitivity to adhesives or unresolved contact dermatitis\n* History of chronic alcohol or drug abuse\n* Pregnant or of child-bearing potential\n* Impulse control disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Change in the Absolute Time Spent \"Off\" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary","description":"Time \"Off\" is defined as when the patient does not have the effect of anti-Parkinson's medication.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.948","spread":"2.587"},{"groupId":"OG001","value":"-2.052","spread":"3.113"},{"groupId":"OG002","value":"-2.138","spread":"2.721"},{"groupId":"OG003","value":"-2.360","spread":"2.608"},{"groupId":"OG004","value":"-1.499","spread":"3.062"}]}]}]},{"type":"SECONDARY","title":"The Change in Relative Time Spent \"Off\" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary","description":"Time \"Off\" is defined as when the patient does not have the effect of anti-Parkinson's medication.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.058","spread":"16.517"},{"groupId":"OG001","value":"-13.463","spread":"20.099"},{"groupId":"OG002","value":"-13.410","spread":"17.202"},{"groupId":"OG003","value":"-14.529","spread":"16.531"},{"groupId":"OG004","value":"-9.250","spread":"18.942"}]}]}]},{"type":"SECONDARY","title":"The Change in the Absolute Time Spent \"on\" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary","description":"Time \"On\" is defined as when the patient has the effect of anti-Parkinson's medication.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.821","spread":"2.655"},{"groupId":"OG001","value":"2.095","spread":"3.120"},{"groupId":"OG002","value":"2.118","spread":"2.827"},{"groupId":"OG003","value":"2.364","spread":"2.876"},{"groupId":"OG004","value":"1.335","spread":"2.975"}]}]}]},{"type":"SECONDARY","title":"The Change in the Relative Time Spent \"on\" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary","description":"Time \"On\" is defined as when the patient has the effect of anti-Parkinson's medication.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.058","spread":"16.517"},{"groupId":"OG001","value":"13.463","spread":"20.099"},{"groupId":"OG002","value":"13.410","spread":"17.202"},{"groupId":"OG003","value":"14.529","spread":"16.531"},{"groupId":"OG004","value":"9.250","spread":"18.942"}]}]}]},{"type":"SECONDARY","title":"The Change in the Status of the Subject After Wake-Up From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.688","spread":"41.607"},{"groupId":"OG001","value":"24.593","spread":"43.006"},{"groupId":"OG002","value":"20.935","spread":"42.132"},{"groupId":"OG003","value":"21.083","spread":"45.642"},{"groupId":"OG004","value":"19.712","spread":"41.857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.667","spread":"18.874"},{"groupId":"OG001","value":"-0.813","spread":"12.804"},{"groupId":"OG002","value":"1.626","spread":"23.659"},{"groupId":"OG003","value":"1.667","spread":"13.417"},{"groupId":"OG004","value":"-0.206","spread":"8.934"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.021","spread":"40.667"},{"groupId":"OG001","value":"-23.780","spread":"43.150"},{"groupId":"OG002","value":"-22.561","spread":"40.519"},{"groupId":"OG003","value":"-22.750","spread":"47.193"},{"groupId":"OG004","value":"-19.506","spread":"43.298"}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II From Baseline to the End of the Maintenance Period","description":"The Unified Parkinson's Disease Rating Scale (UPDRS) Part II is a scale for the assessment of function in Parkinson's disease. UPDRS Part II measures Activities of Daily Living. It consists of 13 questions, each ranging from 0 to 4. The sum score of the UPDRS Part II ranges from 0 to 52. A higher score indicates greater disability. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"4.3"},{"groupId":"OG001","value":"-2.2","spread":"3.9"},{"groupId":"OG002","value":"-1.5","spread":"4.7"},{"groupId":"OG003","value":"-2.1","spread":"4.6"},{"groupId":"OG004","value":"-0.9","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III From Baseline to the End of the Maintenance Period","description":"The Unified Parkinson's Disease Rating Scale (UPDRS) Part III is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Function. It consists of 14 items with 27 questions, each ranging from 0 to 4. The sum score for the UPDRS Part III ranges from 0 to 108. A higher score indicates greater disability. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"7.6"},{"groupId":"OG001","value":"-4.5","spread":"7.5"},{"groupId":"OG002","value":"-3.5","spread":"8.9"},{"groupId":"OG003","value":"-5.9","spread":"7.6"},{"groupId":"OG004","value":"-2.5","spread":"8.2"}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day Are Dyskinesias Present?","description":"Item = Duration (question #32) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - What proportion of the waking day are dyskinesias present? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"69","spread":null},{"groupId":"OG004","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Disability: How Disabling Are the Dyskinesias?","description":"Item = Disability (question #33) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How disabling are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"78","spread":null},{"groupId":"OG004","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Painful Dyskinesias: How Painful Are the Dyskinesias?","description":"Item = Painful Dyskinesia (question #34) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How painful are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"87","spread":null},{"groupId":"OG004","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Presence of Early Morning Dystonia","description":"Item = Presence of Early Morning Dystonia (question #35) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates early morning dystonia.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"76","spread":null},{"groupId":"OG004","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are \"Off\" Periods Predictable?","description":"Item = Are \"off\" periods predictable (question #36) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates \"off\" periods are predictable.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"80","spread":null},{"groupId":"OG004","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are \"Off\" Periods Unpredictable?","description":"Item = Are \"off\" periods unpredictable (question #37) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates \"off\" periods are unpredictable.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"75","spread":null},{"groupId":"OG004","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Do \"Off\" Periods Come on Suddenly?","description":"Item = Do \"off\" periods come on suddenly, within a few seconds (question #38) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates \"off\" periods come on suddenly, within a few seconds.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"67","spread":null},{"groupId":"OG004","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day is the Subject \"Off\", on Average?","description":"Item = What proportion of the waking day is the subject \"off\", on average (question #39) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 - 4 points (4 = maximum). A higher score indicates the subject is \"off\" a larger portion of the waking day.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"55","spread":null},{"groupId":"OG004","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"32","spread":null},{"groupId":"OG004","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Anorexia, Nausea, or Vomiting?","description":"Item = Does the patient have anorexia, nausea, or vomiting (question #40) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has anorexia, nausea, or vomiting.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"90","spread":null},{"groupId":"OG003","value":"85","spread":null},{"groupId":"OG004","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Any Sleep Disturbances Such as Insomnia or Hypersomnolence?","description":"Item = Does the patient have any sleep disturbances such as insomnia or hypersomnolence (question #41) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has sleep disturbances such as insomnia or hypersomnolence.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"77","spread":null},{"groupId":"OG004","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Symptomatic Orthostasis?","description":"Item = Does the patient have symptomatic orthostasis (question #42) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has symptomatic orthostasis.\n\nResults show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"92","spread":null},{"groupId":"OG003","value":"88","spread":null},{"groupId":"OG004","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Number of \"Off\" Periods From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary","description":"Time \"Off\" is defined as when the patient does not have the effect of anti-Parkinson's medication.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.144","spread":"1.687"},{"groupId":"OG001","value":"-1.294","spread":"1.971"},{"groupId":"OG002","value":"-1.323","spread":"1.348"},{"groupId":"OG003","value":"-1.304","spread":"1.442"},{"groupId":"OG004","value":"-1.006","spread":"1.474"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":101},"commonTop":["Nausea","Headache","Dizziness","Dyskinesia","Somnolence"]}}}